Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs.
Mateo
Jose
J
Thrombosis and Hemostasis Unit, Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. jmateo@santpau.es
Badell
Isabel
I
Forner
Ruth
R
Borrell
Montserrat
M
Tizzano
Eduardo
E
Fontcuberta
Jordi
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000097:blood*; D001402:B-Lymphocytes / Q000187:drug effects; D005169:Factor VIII / Q000276:immunology*; D017048:Health Care Costs; D006467:Hemophilia A / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007223:Infant; D008297:Male; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D000069283:Rituximab; D005169:Factor VIII